search
Back to results

Clinical Investigation of the Medtronic Concerto™ Device

Primary Purpose

Congestive Heart Failure, Atrial Arrhythmia, Atrial Tachyarrhythmia, Atrial Fibrillation

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Cardiac Resynchronization Therapy+Implantable Cardioverter Defibrillator
Sponsored by
Medtronic Cardiac Rhythm and Heart Failure
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Congestive Heart Failure, Atrial Arrhythmia, Atrial Tachyarrhythmia, Atrial Fibrillation focused on measuring congestive heart failure, atrial arrhythmia, cardiac resynchronization therapy, implantable cardioverter defibrillator

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Subjects who require the implantation of an Implantable Cardioverter Defibrillator Subjects who have heart failure that severely limits daily activities (NYHA Class III) or Subjects who have severe heart failure and should always be resting (NYHA Class IV) Subjects with reduced heart pumping function (left ventricular ejection fraction ≤ 35%) Exclusion Criteria: Subjects who have constant atrial fibrillation (top chambers of the heart beat too fast continuously) Subjects who are post-heart transplant

Sites / Locations

Outcomes

Primary Outcome Measures

Complication rate
Atrial defibrillation effectiveness

Secondary Outcome Measures

Change in patient health status during the study
System performance
Adverse events

Full Information

First Posted
December 21, 2005
Last Updated
September 22, 2008
Sponsor
Medtronic Cardiac Rhythm and Heart Failure
search

1. Study Identification

Unique Protocol Identification Number
NCT00268320
Brief Title
Clinical Investigation of the Medtronic Concerto™ Device
Official Title
Clinical Investigation of the Medtronic Concerto™ Cardiac Resynchronization Therapy (CRT) and Implantable Cardioverter Defibrillator (ICD) Therapies (CRT+ICD Device)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2008
Overall Recruitment Status
Completed
Study Start Date
January 2006 (undefined)
Primary Completion Date
June 2006 (Actual)
Study Completion Date
July 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Medtronic Cardiac Rhythm and Heart Failure

4. Oversight

5. Study Description

Brief Summary
Heart failure is a progressive disease that decreases the pumping action of the heart. This may cause a backup of fluid in the heart and may result in heart beat changes. When there are changes in the heart beat sometimes an implantable heart device is used to control the rate and rhythm of the heart beat. In certain heart failure cases, when the two lower chambers of the heart no longer beat in a coordinated manner, cardiac resynchronization therapy may be prescribed. People who have a dangerously fast heart beat, or whose heart is at risk of stopping beating, may be in need of an electronic device called an implantable cardioverter defibrillator (ICD). Atrial tachyarrhythmia (AT) is the name for rapid beats in the upper chambers of the heart. People with AT may experience symptoms such as heart palpitations (a racing or pounding feeling in the chest), shortness of breath, dizziness, fatigue or weakness. The purpose of this study is to study an investigational implantable device containing Cardiac Resynchronization Therapy (CRT) and Implantable Cardioverter Defibrillator (ICD) therapies (CRT+ICD device) in subjects who are at significant risk of developing atrial tachyarrhythmias.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Congestive Heart Failure, Atrial Arrhythmia, Atrial Tachyarrhythmia, Atrial Fibrillation
Keywords
congestive heart failure, atrial arrhythmia, cardiac resynchronization therapy, implantable cardioverter defibrillator

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
270 (false)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
Cardiac Resynchronization Therapy+Implantable Cardioverter Defibrillator
Primary Outcome Measure Information:
Title
Complication rate
Title
Atrial defibrillation effectiveness
Secondary Outcome Measure Information:
Title
Change in patient health status during the study
Title
System performance
Title
Adverse events

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects who require the implantation of an Implantable Cardioverter Defibrillator Subjects who have heart failure that severely limits daily activities (NYHA Class III) or Subjects who have severe heart failure and should always be resting (NYHA Class IV) Subjects with reduced heart pumping function (left ventricular ejection fraction ≤ 35%) Exclusion Criteria: Subjects who have constant atrial fibrillation (top chambers of the heart beat too fast continuously) Subjects who are post-heart transplant
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Not required for IDE studies
Facility Information:
City
Anchorage
State/Province
Alaska
Country
United States
City
Phoenix
State/Province
Arizona
Country
United States
City
Santa Monica
State/Province
California
Country
United States
City
Jacksonville
State/Province
Florida
Country
United States
City
Orlando
State/Province
Florida
Country
United States
City
Pensacola
State/Province
Florida
Country
United States
City
Atlanta
State/Province
Georgia
Country
United States
City
Evanston
State/Province
Illinois
Country
United States
City
Fort Wayne
State/Province
Indiana
Country
United States
City
Des Moines
State/Province
Iowa
Country
United States
City
Brighton
State/Province
Massachusetts
Country
United States
City
Detroit
State/Province
Michigan
Country
United States
City
St. Paul
State/Province
Minnesota
Country
United States
City
Kansas City
State/Province
Missouri
Country
United States
City
St. Louis
State/Province
Missouri
Country
United States
City
Newark
State/Province
New Jersey
Country
United States
City
Albuquerque
State/Province
New Mexico
Country
United States
City
Syracuse
State/Province
New York
Country
United States
City
Cincinnati
State/Province
Ohio
Country
United States
City
Cleveland
State/Province
Ohio
Country
United States
City
Oklahoma City
State/Province
Oklahoma
Country
United States
City
Pittsburgh
State/Province
Pennsylvania
Country
United States
City
West Reading
State/Province
Pennsylvania
Country
United States
City
Charleston
State/Province
South Carolina
Country
United States
City
Nashville
State/Province
Tennessee
Country
United States
City
Austin
State/Province
Texas
Country
United States
City
Fort Worth
State/Province
Texas
Country
United States
City
Richmond
State/Province
Virginia
Country
United States
City
Tacoma
State/Province
Washington
Country
United States
City
Morgantown
State/Province
West Virginia
Country
United States
City
Linz
Country
Austria
City
St. Poelten
Country
Austria
City
Copenhagen
Country
Denmark
City
Aachen
Country
Germany
City
Bernau
Country
Germany
City
Bochum
Country
Germany
City
Goettingen
Country
Germany
City
Heidelberg
Country
Germany
City
Muenster
Country
Germany
City
Patras
Country
Greece
City
Negrar
State/Province
Veneto
Country
Italy
City
Bologna
Country
Italy
City
Tsukuba
State/Province
Ibaraki
Country
Japan
City
Suita
State/Province
Osaka
Country
Japan
City
Shinjuku-ku
State/Province
Tokyo
Country
Japan
City
Eindhoven
Country
Netherlands
City
Rotterdam
Country
Netherlands
City
Oslo
Country
Norway
City
Valencia
Country
Spain
City
Basel
Country
Switzerland
City
Southhampton
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Clinical Investigation of the Medtronic Concerto™ Device

We'll reach out to this number within 24 hrs